Edition:
United States

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

17.30USD
4:00pm EDT
Change (% chg)

$0.50 (+2.98%)
Prev Close
$16.80
Open
$16.55
Day's High
$17.40
Day's Low
$16.55
Volume
82,874
Avg. Vol
61,395
52-wk High
$20.64
52-wk Low
$7.68

Latest Key Developments (Source: Significant Developments)

Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease
Wednesday, 8 Mar 2017 08:00am EST 

Intersect ENT Inc : Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease . Intersect ENT - Trial met both co-primary efficacy endpoints, demonstrating a statistically significant reduction in nasal congestion and polyp burden .Intersect ENT Inc - Submission supported by four clinical studies evaluating safety and effectiveness.  Full Article

Intersect Ent Q4 loss per share $0.17
Tuesday, 28 Feb 2017 04:05pm EST 

Intersect Ent Inc : Intersect ENT reports fourth quarter and full year 2016 results . Q4 loss per share $0.17 . Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S . Sees q1 revenue $19 million to $19.5 million . Sees fy 2017 revenue $87 million to $89 million . Q4 revenue $24.2 million versus i/b/e/s view $23.5 million . Intersect ent inc says expects full year 2017 gross margin of approximately 83%-84% and operating expenses of approximately $96-$98 million .Fy2017 earnings per share view $-0.69, revenue view $87.6 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect ENT says FDA approves steroid releasing implant Propel Contour
Friday, 24 Feb 2017 08:00am EST 

Intersect Ent Inc : Intersect ENT announces FDA approval of newest steroid releasing implant, Propel Contour, for use in treating the frontal and maxillary sinuses . Intersect ENT Inc - expects to launch propel contour broadly in Q2 of 2017 and maintains its previously stated 2017 revenue guidance of $87-$89 million .FY2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect Q2 loss per share $0.21
Tuesday, 2 Aug 2016 04:05pm EDT 

Intersect ENT Inc : Q2 loss per share $0.21 . Q2 revenue $19.3 million versus I/B/E/S view $18.8 million . Intersect ENT reports second quarter 2016 results . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Sees Q3 2016 revenue about $17.8 million . Fy2016 revenue view $78.3 million, q3 revenue view $18.4 million -- Thomson Reuters I/B/E/S .Expects full year revenue at low end of previous guidance range of $78 million-$80 million.  Full Article

Intersect ENT announces FDA submission of NOVA
Monday, 1 Aug 2016 07:58am EDT 

Intersect ENT Inc :Intersect ENT announces FDA submission of NOVA bioabsorbable steroid releasing implant for patients with chronic sinus disease.  Full Article

BRIEF-Intersect ENT prelim Q2 revenue $19.3 mln
Monday, 18 Jul 2016 08:00am EDT 

Corrects third bullet to preliminary revenue, not reported revenue.Intersect Ent Inc : Says company's Chief Commercial Officer Chas McKhann is departing for personal reasons . Announces preliminary Q2 revenue and business update .Q2 preliminary revenue $19.3 million versus I/B/E/S view$18.8 million.  Full Article

Intersect ENT Inc reaffirms FY 2016 revenue guidance
Thursday, 5 May 2016 04:05pm EDT 

Intersect ENT Inc:Continues to project revenue for FY 2016 in the range of $78-$80 million.  Full Article

Intersect ENT Inc gives Q4, FY 2015 revenue guidance; gives FY 2016 revenue guidance
Monday, 11 Jan 2016 04:05pm EST 

Intersect ENT Inc:Anticipates revenue for the Q4 2015 in the range of $18.6 to $18.8 million.Anticipates revenue for the FY 2015 of approximately $61.4 to $61.6 million.Continues to expect significant revenue growth in FY 2016 and forecasts revenue to be between $78 and $80 million.  Full Article

Intersect ENT Inc Announces Positive Clinical Results from Three Studies Evaluating Steroid Releasing Implants Placed in the Physician's Office
Monday, 28 Sep 2015 08:00am EDT 

Intersect ENT Inc:Announces positive clinical results from three studies evaluating steroid releasing implants placed in the physician's office.Findings included a statistically significant improvement in patient symptoms observed at four weeks, which were sustained to 12 weeks.  Full Article

Intersect ENTsays positive preliminary clinical results for PROPEL Mini Steroid Releasing Implant
Monday, 17 Aug 2015 09:00am EDT 

Intersect ENT Inc:Announces positive preliminary clinical results for the propel mini steroid releasing implant in patients with frontal sinus disease.Says the study met its primary efficacy endpoint.  Full Article

More From Around the Web

BRIEF-Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease

* Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease